{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:59:21Z","timestamp":1790657961620,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Circulating tumor cells (CTCs) are closely associated with the progression of hepatocellular carcinoma (HCC). However, the clinical value of CTC detection in patients receiving systemic therapy for advanced HCC remains to be fully elucidated. A total of 125 patients with advanced HCC who underwent systemic therapy were enrolled in this study. Five milliliters of peripheral blood were collected at five time points: before treatment initiation, and 1 month, 3 months, 6 months, and 1 year after treatment. CTCs were isolated and captured using the Isolation by Size of Epithelial Tumor Cells (ISET) method. Tumor response to systemic treatment was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). We further analyzed the correlation between dynamic changes in peripheral blood CTC levels and tumor response to systemic therapy. The overall objective response rate (ORR) and disease control rate (DCR) were 39.2% (49\/125) and 82.4% (103\/125), respectively. Dynamic monitoring of CTCs revealed that CTC levels remained persistently high and gradually increased in patients with progressive disease (PD). In patients with complete response (CR) or partial response (PR), CTC levels decreased progressively during treatment and stayed at low levels thereafter. For patients with stable disease (SD), CTC counts began to decline 3 months after treatment but remained higher than those in patients with CR or PR. Baseline CTC levels were negatively correlated with treatment efficacy: patients with higher baseline CTC counts exhibited poorer tumor responses. Patients with baseline CTC counts &amp;lt; 15, CTC counts &amp;lt; 13 at 1 month post-treatment, and CTC counts &amp;lt; 10 at 3 months post-treatment were more likely to achieve an objective tumor response and obtained better therapeutic outcomes. Additionally, these patients had significantly longer progression-free survival (PFS) and overall survival (OS) compared with those who exceeded the above cut-off values. Peripheral blood CTC counts are correlated with tumor treatment response in patients with advanced HCC. Serial CTC detection serves as a valuable tool for evaluating the efficacy of systemic therapy in advanced HCC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1917039","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:35:04Z","timestamp":1790656504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiangmin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan Hospital of Traditional Chinese and Western Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, People\u2019s Hospital of Dongxihu District","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan Hospital of Traditional Chinese and Western Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Wuhan Hospital of Traditional Chinese and Western Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107313","article-title":"Hepatocellular carcinoma","volume":"50","author":"Dopazo","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.11","article-title":"Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States","volume":"109","author":"Altekruse","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3978\/j.issn.2304-3881.2015.08.05","article-title":"Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States","volume":"5","author":"Xu","year":"2016","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1453806","article-title":"Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry","volume":"12","author":"Zhang","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01647-1","article-title":"Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"17","author":"Chen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/nejmoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0541","article-title":"Liquid biopsy in hepatocellular carcinoma: challenges, advances, and clinical implications","volume":"31","author":"Park","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2025.102632","article-title":"Circulating tumor DNA in peripheral blood may predict the efficacy of immune-targeted therapy in patients with hepatocellular carcinoma","volume":"49","author":"Zheng","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.025","article-title":"TGF-\u03b21-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12","volume":"167","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12964-022-00872-w","article-title":"M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma","volume":"21","author":"Lu","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71968","article-title":"Altered metabolites in hepatocellular carcinoma (HCC) paving the road for metabolomics signature and biomarkers for early diagnosis of HCC","volume":"16","author":"Al-Amodi","year":"2024","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189714","article-title":"Liquid biopsy in melanoma: significance in diagnostics, prediction and treatment monitoring","volume":"22","author":"Kami\u0144ska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41419-023-05757-5","article-title":"Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102979","article-title":"Advancements in liquid biopsy for breast cancer: molecular biomarkers and clinical applications","volume":"139","author":"Qiu","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073752","article-title":"Circulating cancer-associated macrophage-like cells as a blood-based biomarker of response to immune checkpoint inhibitors","volume":"25","author":"Magri","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18111840","article-title":"Liquid biopsy biomarkers for predicting and monitoring immunotherapy response in lung cancer","volume":"18","author":"Serio","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3892\/etm.2024.12583","article-title":"Detection of PD-L1 expression and epithelial-mesenchymal transition of circulating tumor cells in non-small cell lung cancer","volume":"28","author":"Jiang","year":"2024","journal-title":"Exp Ther Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169427","article-title":"Technical insights into highly sensitive isolation and molecular characterization of fixed and live circulating tumor cells for early detection of tumor invasion","volume":"12","author":"Laget","year":"2017","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0002-9440(10)64706-2","article-title":"Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells","volume":"156","author":"Vona","year":"2000","journal-title":"Am J Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1186\/s12885-020-07488-8","article-title":"Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-1753","article-title":"Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s175489","article-title":"Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma","volume":"10","author":"Ye","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i4.689","article-title":"Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: a retrospective study","volume":"15","author":"Zhou","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-021-00801-z","article-title":"EMT and inflammation: crossroads in HCC","volume":"54","author":"Sengez","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.9838","article-title":"Effects of UPF1 expression on EMT process by targeting E-cadherin, N-cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line","volume":"19","author":"Li","year":"2019","journal-title":"Mol Med Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353787","article-title":"Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy","volume":"15","author":"Nicolini","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-021-24386-0","article-title":"Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-022-04796-8","article-title":"EGFR\/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli","volume":"13","author":"Song","year":"2022","journal-title":"Cell Death Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-1063","article-title":"Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma","volume":"24","author":"Sun","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1917039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:35:13Z","timestamp":1790656513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1917039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":39,"alternative-id":["10.3389\/fonc.2026.1917039"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1917039","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1917039"}}